Max Access Solutions (with The Max Foundation)
Various Cancers
Key Facts
About Tanner Pharma Group
Tanner Pharma Group is a privately held, revenue-generating services company that acts as a critical enabler in the global pharmaceutical supply chain. It partners with pharmaceutical companies, biotechs, and non-profits to navigate complex regulatory, logistical, and distribution challenges, ensuring patients can access medicines through expanded access programs, clinical trial supply, and international commercialization. With a mission-driven focus on health equity, the company leverages two decades of experience and a global network to manage drug shortages, post-trial supply, and market entry strategies for its partners. Its business model is entirely service-based, providing tailored solutions rather than developing its own therapeutic pipeline.
View full company profileTherapeutic Areas
Other Various Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Oncology/Immuno-oncology Portfolio | MSD | Phase III/Commercial |
| Bevacizumab Biosimilar | Dr. Reddy's Laboratories | Approved |
| LADR Platform | LadRx | Preclinical |
| NK Cell Stimulation (via JadiCell) | Therapeutic Solutions International | Preclinical |
| Zip-Code Library for Oncology | Kodikaz Therapeutic Solutions | Pre-clinical |
| Proprietary RLT Pipeline | Affibody | Not Specified (Preclinical-Phase 2) |
| Preclinical ASO Portfolio | Isarna Therapeutics | Preclinical |
| SPACE-GM Microenvironment Analysis | Enable Medicine | Research |
| Oncology Program(s) | CIS Pharma | Pre-clinical |
| CPA Platform in Oncology | InnoSIGN | Development |
| Oncology Services | Transcure Bioservices | Preclinical |
| SBX 2021 | Stramsen Biotech | Early-stage Clinical |